Hepatitis B Surface Antigen Seroclearance Rate After Stopping Nucleos(t)ide Analogues in Chronic Hepatitis B—A Systematic Review and Meta‐Analysis
Journal of Gastroenterology and Hepatology · 2025-05 · 40 (5) · 1079-1104
DOI: 10.1111/jgh.16920 ↗Kurz gefasst
Metaanalyse in der Zeitschrift Journal of Gastroenterology and Hepatology, online erschienen am 05.03.2025. Verfasst von Soe Thiha Maung und 2 weiteren Autor:innen. Beteiligte Einrichtung: Division of Gastroenterology, Department of Medicine, King Chulalongkorn Memorial Hospital and Thai Red Cross Society, Faculty of Medicine, Chulalong…. Hauptthemen laut MEDLINE: Antiviral Agents, Hepatitis B Surface Antigens, Hepatitis B, Chronic, Nucleosides. Die Arbeit wurde bisher 7-mal zitiert (Crossref) und nennt 104 Literaturangaben.
Abstract (Originalsprache)
Aim
To identify factors influencing HBsAg seroclearance rates after stopping nucleos(t)ide analogue (NA) therapy in patients with chronic hepatitis B (CHB).
Methods
We conducted a comprehensive literature search in databases from inception to July 2024. Subgroup analyses and meta‐regression were performed to determine factors associated with HBsAg seroclearance, including ethnicity, HBV genotype, NA therapy duration, end‐of‐treatment (EOT) qHBsAg levels, HBeAg status, cirrhosis status, and follow‐up duration.
Results
The meta‐analysis included 62 studies ( n = 9867) with a pooled HBsAg seroclearance rate of 10% (95%CI: 8%–12%, I 2 = 92%) after NA cessation. HBeAg‐negative patients showed significantly higher rates than HBeAg‐positive patients (11% vs. 5%, p = 0.030). Subgroup analysis revealed higher seroclearance with follow‐up of >5 years (18%, p = 0.004), showing significantly higher rates were observed in studies with longer follow‐up periods. Caucasians showed a higher rate (12%) than Asians (9%, p = 0.067). Studies adhering to AASLD, EASL, or APASL stopping rules showed no significant differences in rates. Patients with EOT qHBsAg ≤2.0 log IU/mL had higher rates (23%) than those with >2.0 log IU/mL (11%). Re‐treated patients had lower seroclearance (6%) compared to those not re‐treated (17%, p = 0.178). Meta‐regression identified ethnicity, HBeAg status, and follow‐up duration as significant contributors to heterogeneity. Egger's test showed no evidence of publication bias ( p = 0.1928).
Conclusion
Our meta‐analysis highlights the role of ethnicity, EOT qHBsAg levels, HBeAg‐status, and follow‐up duration in determining HBsAg seroclearance rates. These findings stress the need for personalized NA discontinuation strategies and further research on HBV genotypes and biomarkers to improve treatment outcomes and predict seroclearance more accurately.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Division of Gastroenterology, Department of Medicine, King Chulalongkorn Memorial Hospital and Thai Red Cross Society, Faculty of Medicine, Chulalongkorn University, Bangkok, Thailand.
- Ma Har Myaing Hospital, Yangon, Myanmar.
- Division of Academic Affairs, Faculty of Medicine, Chulalongkorn University, Bangkok, Thailand.
- Center of Excellence for Innovation and Endoscopy in Gastrointestinal Oncology, Faculty of Medicine, Chulalongkorn University, Bangkok, Thailand.
ORCID-Profile: Roongruedee Chaiteerakij
Zitieren
APA
Maung, S. T., Decharatanachart, P., & Chaiteerakij, R. (2025). Hepatitis B Surface Antigen Seroclearance Rate After Stopping Nucleos(t)ide Analogues in Chronic Hepatitis B—A Systematic Review and Meta‐Analysis. Journal of Gastroenterology and Hepatology, 40(5), 1079-1104. https://doi.org/10.1111/jgh.16920
Vancouver
Maung ST, Decharatanachart P, Chaiteerakij R. Hepatitis B Surface Antigen Seroclearance Rate After Stopping Nucleos(t)ide Analogues in Chronic Hepatitis B—A Systematic Review and Meta‐Analysis. Journal of Gastroenterology and Hepatology. 2025;40(5):1079-1104. doi:10.1111/jgh.16920
BibTeX
@article{Maung2025,
author = {Maung, Soe Thiha and Decharatanachart, Pakanat and Chaiteerakij, Roongruedee},
title = {Hepatitis B Surface Antigen Seroclearance Rate After Stopping Nucleos(t)ide Analogues in Chronic Hepatitis B—A Systematic Review and Meta‐Analysis},
journal = {Journal of Gastroenterology and Hepatology},
year = {2025},
volume = {40},
number = {5},
pages = {1079--1104},
doi = {10.1111/jgh.16920}
}
EUVIMED